Barclays raises target price to $27 from $20 for Doximity (DOCS.N)

Barclays PLC has raised its price target for Doximity, Inc. (DOCS.N) from $20 to $27, reflecting a more optimistic outlook for the healthcare technology company. The upgrade comes amid broader market stabilization and signs of growth in the healthcare IT sector. While the firm did not immediately adjust its overall rating, the increased target price signals improved confidence in Doximity’s long-term potential. Analysts have pointed to the company’s expanding digital health platform and growing adoption among healthcare professionals as key drivers of future performance. The move aligns with recent analyst activity across the sector, including upgrades and revised forecasts for several healthcare and technology firms. Investors are now closely watching Doximity’s upcoming earnings and strategic developments to gauge whether the stock can sustain momentum following the upgrade. The stock has shown mixed performance in recent after-market sessions, influenced by broader market trends and sector-specific dynamics.